Hcw Biologics, Inc. (HCWB)
NASDAQ:HCWB
Top Page
HCW Biologics
(NASDAQ:HCWB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.26
▼(-93.48% Downside)
Action:ReiteratedDate:04/01/26
The score is primarily weighed down by deteriorating financial performance (shrinking revenue, very large losses, and ongoing cash burn) and bearish technicals (price well below key moving averages and negative MACD). Corporate events provide some near-term positives via licensing cash and regained listing compliance, but financing dependence and weak fundamentals keep the overall score low.
Positive Factors
Non-dilutive licensing & China JV
The $7M upfront license and equity stake shift Phase 1 development costs for HCW11-006 to a China JV, providing non-dilutive capital, lowering near-term cash burn, and creating milestone/royalty upside. This structurally de-risks that asset and extends runway for other programs.
Negative Factors
Severe revenue contraction & losses
A dramatic revenue decline and extreme net losses reflect limited or no recurring product revenue and high operating/R&D spend. This reduces internal funding capacity, weakens investor confidence, and makes the company heavily reliant on external financing or partner deals to sustain development.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive licensing & China JV
The $7M upfront license and equity stake shift Phase 1 development costs for HCW11-006 to a China JV, providing non-dilutive capital, lowering near-term cash burn, and creating milestone/royalty upside. This structurally de-risks that asset and extends runway for other programs.
Read all positive factors
HCW Biologics (HCWB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.84M
Dividend YieldN/A
Average Volume (3M)16.73M
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue Growth-87.93%
EPS Growth65.26%
CountryUS
Employees36
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.02
Shares Outstanding6,734,104
10 Day Avg. Volume977,640
30 Day Avg. Volume16,725,749
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.74
Price to Sales (P/S)37.54
P/FCF Ratio-0.15
Enterprise Value/Market Cap2.95
Enterprise Value/Revenue100.06
Enterprise Value/Gross Profit-33.28
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$2.00Price Target Upside-49.87% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$900.00K
HCW Biologics Business Overview & Revenue Model
Company Description
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an ...
How the Company Makes Money
HCW Biologics is a clinical-stage company and, based on publicly available information, does not have marketed commercial products; as a result, it typically does not generate recurring product sales revenue. Its ability to make money is therefore...
HCW Biologics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
32
Negative
Cash Flow
12
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 54.23K | 2.57M | 2.84M | 6.72M | 0.00 |
| Gross Profit | 10.85K | 959.40K | 560.36K | 2.59M | -543.60K |
| EBITDA | -13.16M | -27.68M | -23.58M | -14.06M | -12.32M |
| Net Income | -22.30M | -30.02M | -24.99M | -14.90M | -12.86M |
Balance Sheet | |||||
| Total Assets | 24.52M | 30.24M | 28.51M | 46.81M | 53.51M |
| Cash, Cash Equivalents and Short-Term Investments | 1.95M | 4.67M | 3.60M | 32.06M | 36.71M |
| Total Debt | 6.81M | 13.69M | 6.30M | 6.41M | 0.00 |
| Total Liabilities | 21.76M | 37.01M | 15.05M | 9.38M | 2.32M |
| Stockholders Equity | 2.76M | -6.77M | 13.46M | 37.43M | 51.19M |
Cash Flow | |||||
| Free Cash Flow | -13.39M | -14.49M | -28.72M | -20.66M | -11.02M |
| Operating Cash Flow | -13.39M | -14.23M | -22.51M | -10.39M | -10.98M |
| Investing Cash Flow | 0.00 | -261.62K | 3.80M | 14.71M | -35.02M |
| Financing Cash Flow | 10.67M | 15.57M | -14.53K | 6.27M | 49.27M |
HCW Biologics Technical Analysis
Negative
3.99
Price Trends
0.72
Negative
1.25
Negative
2.74
Negative
Market Momentum
-0.13
Positive
32.83
Neutral
8.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HCWB, the sentiment is Negative. The current price of 3.99 is above the 20-day moving average (MA) of 0.53, above the 50-day MA of 0.72, and above the 200-day MA of 2.74, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 32.83 is Neutral, neither overbought nor oversold. The STOCH value of 8.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HCWB.
HCW Biologics Risk Analysis
HCW Biologics disclosed 48 risk factors in its most recent earnings report. HCW Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
HCW Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $7.30M | -1.12 | -71.27% | ― | -72.15% | -223.62% | |
50 Neutral | $7.33M | -1.38 | -60.33% | ― | 13.30% | 22.70% | |
46 Neutral | $8.53M | -0.31 | -32.58% | ― | -100.00% | -463.97% | |
45 Neutral | $1.84M | -0.09 | 1121.04% | ― | -87.93% | 65.26% | |
42 Neutral | $3.22M | -0.29 | -157.24% | ― | ― | 25.19% | |
40 Underperform | $2.63M | -0.52 | ― | ― | ― | 87.42% |
* Healthcare Sector Average
HCWB
HCW Biologics
0.27
-8.29
-96.81%
KPRX
Kiora Pharmaceuticals
2.16
-0.49
-18.49%
MTNB
Matinas BioPharma
0.50
>-0.01
-1.57%
XBIO
Xenetic Biosciences
3.20
0.90
39.13%
ADXN
Addex Therapeutics
6.10
-0.41
-6.30%
CLDI
Calidi Biotherapeutics
0.24
-4.87
-95.28%
HCW Biologics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Secures $7M License Deal for HCW11-006
Positive
Mar 17, 2026
On March 17, 2026, HCW Biologics Inc., a U.S.-based commercial- and clinical-stage biopharmaceutical company developing fusion immunotherapies for autoimmune disease, cancer and senescence-associated dysplasia, reported it had received full paymen...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight
Positive
Mar 2, 2026
HCW Biologics Inc., a clinical-stage biopharmaceutical developer of novel immunotherapies targeting chronic inflammation and age-related, senescence-associated diseases, is advancing a pipeline led by HCW9302, an IL-2 fusion molecule in Phase 1 fo...
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Completes Follow-On Offering to Fund Pipeline
Positive
Feb 19, 2026
On February 17, 2026, HCW Biologics Inc. entered into a securities purchase agreement with a single institutional investor for a follow-on public offering of 2,477,292 units, each comprising a common share or pre-funded warrant plus a common stock...
Business Operations and StrategyPrivate Placements and Financing
HCW Biologics Licenses TRBC Asset to China JV Trimmune
Positive
Feb 13, 2026
On February 13, 2026, HCW Biologics and China-based WY Biotech announced an exclusive worldwide license agreement granting newly formed Beijing Trimmune Biotech rights to develop and commercialize in vivo applications of HCW11-006, a preclinical T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.